Equity Research X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Should You Buy Check-Cap Ltd. Stock in 2026?

By CirclFi Research Team · · 11/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Check-Cap Ltd. (MBAI) sits in the bottom tier of our quality coverage with a score of 2.3/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $0.95.

The short answer: 6 of 11 CirclFi valuation models project upside for Check-Cap Ltd. (MBAI) at $0.95 — the model consensus leans bullish, with a Quality Score of 2.3/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 6 of 11 models see upside — majority bullish
  • Quality Score: 2.3/10 — Very Weak — significant concerns
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $0.24 – $2.48 (916% spread)

Bullish Models

6 / 11

Bearish Models

5 / 11

Quality Score

2.3 /10

Very Weak — significant concerns

Value Trap Risk

/100
Not scored

Not scored

Model Consensus

11 /13
Active Models

Avg. confidence: 16%

Investment Thesis

The Bull Case

Target: $2.48 (+160.6% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $0.95 and the composite fair value of $1.25 implies +32.1% upside potential.
  • According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $2.48 (+160.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.24 (-74.3%)

  • According to the CirclFi Quality of Company (QOC) framework, Check-Cap Ltd.'s rating of 2.3/10 indicates below-average quality, raising questions about sustainable earnings levels.
  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $0.24 (-74.3%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +235.0% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

Peer Benchmarking

GEHC GE HealthCare Techno
8.4
BFLY Butterfly Network, I
6.8
PHG Koninklijke Philips
6.1
NNOX NANO-X IMAGING LTD
5.6

Valuation Divergence

Spread

916%

Fair Value Range

$0.24 – $2.48

A 916% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Regime Cross

$2.48 (+160.6%)

Most Bearish

Dynamic NAV

$0.24 (-74.3%)

Key Risk Factors

Weak Fundamentals

QOC 2.3/10 signals below-average quality.

Model Disagreement

916% spread signals high variance in projections.

Macro/Sector Risk

X-Ray Apparatus & Tubes & Related Irradiation Apparatus headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View MBAI Data Page →

The Bottom Line

Our models don't have a clear verdict on Check-Cap Ltd.. At $0.95 vs. $1.25 composite fair value, the average upside of +32.1% masks significant model disagreement (+235.0% spread). With quality at 2.3/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.

These are quantitative model outputs, not investment recommendations. Check-Cap Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy MBAI stock right now?

Based on CirclFi's multi-model analysis, 6 of 11 models see upside for MBAI at $0.95. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 2.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Check-Cap Ltd.?

Key risks include: a below-average Quality Score of 2.3/10, indicating fundamental weakness; wide model disagreement (916% spread), signaling high uncertainty; general market and sector-specific risks affecting X-Ray Apparatus & Tubes & Related Irradiation Apparatus companies. Always diversify and consult a financial advisor.

How does MBAI compare to its competitors?

Among X-Ray Apparatus & Tubes & Related Irradiation Apparatus peers, MBAI holds a Quality Score of 2.3/10. Comparable companies include GEHC (QOC 8.4), BFLY (QOC 6.8), PHG (QOC 6.1). The relative ranking helps investors identify whether MBAI offers better fundamental quality than alternatives in the same sector.

Is MBAI a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MBAI's Quality Score of 2.3/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy MBAI at?

CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $0.24 to $2.48. At $0.95, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for MBAI.

View MBAI Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →